Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseIND Approval |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase I Clinical Trial of PD-1 Knockout Engineered T Cells Treating Patients With Advanced Non-small Cell Lung Cancer
This study will evaluate the safety of PD-1 knockout engineered T cells in treating metastatic non-small cell lung cancer. Blood samples will also be collected for research purposes.
100 Clinical Results associated with Chengdu MedGenCell, Co., Ltd.
0 Patents (Medical) associated with Chengdu MedGenCell, Co., Ltd.
100 Deals associated with Chengdu MedGenCell, Co., Ltd.
100 Translational Medicine associated with Chengdu MedGenCell, Co., Ltd.